Skip to main content

Table 9 Thyroid cancer and melanoma

From: Role of maspin in cancer

Authors Years N. patients Maspin expression Clinical features/prognosis/predictive factors
Boltze et al. 2004 68 (papillary carcinomas) 70.5% positive maspin Positive maspin in papillary cancer = 2% p53+, 83% 110 months OS, Recurrence free disease: 60 months
   38 (follicular carcinomas) 100% negative maspin Negative maspin in follicular carcinomas = 80%p53+, 40% 110 months OS, Recurrence free disease :40months
Tahany et al. 2006 63(thyroid specimes)= 28.5%positive maspin Positive maspin = 72% papillary thyroid, 61,1% positive cytoplasm and positive nucleus, 11.1 % positive nucleus and 27.8% positive cytoplasm,
   25 papillary carcinoma 71.5% negative maspin  
Wada et al. 2004 45 (malignant melanoma) 12.5% positive maspin  
    87.5% negative maspin Negative maspin in melanoma = 83% trunk, 89% extremites, 89% acral, 86% lentigo maligna melanoma, 100% nodular melanoma, 75% superficial spreading, 100% thickness 1.0-4.0 and >4 mm, 100% II-III-IV stage
Chua et al. 2009 77(malignant melanoma) 59.7% positive maspin Positive maspin = less microvessel density, 78% thin melanoma, 46% thick melanoma
    35.1% negative maspin Negative maspin = high microvessel density, 22% thin melanomas, 54% thick melanoma